On September 10, 2015, Takayama, Tetsuo; Shibata, Tsuyoshi; Shiozawa, Fumiyasu; Kawabe, Kenichi; Shimizu, Yuki; Hamada, Makoto; Hiradate, Akira; Takahashi, Masato; Ushiyama, Fumihito; Oi, Takahiro; Shirasaki, Yoshihisa; Matsuda, Daisuke; Koizumi, Chie; Kato, Sota published a patent.Synthetic Route of 362703-57-9 The title of the patent was Pharmaceutical compositions containing N-[[1-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl]glycine as prolyl hydroxylase 2 (PHD2) inhibitor. And the patent contained the following:
Oral solid pharmaceutical compositions contain N-[[1-[[6-(4-chlorophenoxy)-3-pyridinyl]methyl]-4-hydroxy-2-oxo-1,2,5,6-tetrahydro-3-pyridinyl]carbonyl]glycine or its pharmaceutically acceptable salt as active ingredient. The compound inhibits PHD2, thus useful for prevention and treatment of anemia. The experimental process involved the reaction of tert-Butyl 4-amino-4-(2-methoxy-2-oxoethyl)piperidine-1-carboxylate(cas: 362703-57-9).Synthetic Route of 362703-57-9
The Article related to tetrahydropyridinylcarbonylglycine preparation antianemic prolyl hydroxylase inhibitor oral solid, Pharmacology: Effects Of Cardiovascular, Hematologic, and Renal Drugs and other aspects.Synthetic Route of 362703-57-9
Referemce:
Piperidine – Wikipedia,
Piperidine | C5H11N – PubChem